# Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

> **NCT05027425** · PHASE2 · TERMINATED · sponsor: **University of Cincinnati** · enrollment: 8 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Cirrhosis
- Portal Hypertension

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **PROCEDURE:** Liver Transplant

## Key facts

- **NCT ID:** NCT05027425
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-07
- **Primary completion:** 2024-11-07
- **Final completion:** 2024-11-07
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study is closing due to low enrollment and feasibility of the study.
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027425, "Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05027425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*